Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease

American Journal of Nephrology
Tsukasa NakamuraKoichi Node

Abstract

Urinary liver-type fatty-acid-binding protein (L-FABP) is a useful clinical marker in the monitoring of chronic kidney disease (CKD) associated with tubulointerstitial damage. Statins have been shown to be effective in the treatment of renal disease. The aim of the present study was to determine whether pitavastatin, a newly developed statin, modulates the urinary L-FABP levels in normolipidemic patients with CKD. Thirty normolipidemic mild CKD patients (18 males and 12 females, mean age 40 years, mean serum creatinine level 1.0 mg/dl) were randomly assigned to two groups: (1) pitavastatin (1 mg/day, n = 15) and (2) placebo (n = 15). Urinary protein and urinary L-FABP levels were measured before the initiation of treatment and 3 and 6 months thereafter. Twenty age-matched healthy subjects were also studied as controls. Before treatment, the urinary L-FABP levels in 30 CKD patients (84.0 +/- 68.5 microg/g creatinine) were significantly higher than those of healthy subjects (6.4 +/- 4.2 mug/g creatinine; p < 0.001). Pitavastatin slightly reduced serum total cholesterol and triglyceride levels, but this was not statistically significant. However, pitavastatin reduced the urinary protein excretion from 1.8 to 1.0 g/day (p < 0.01), ...Continue Reading

References

Jan 3, 2001·Kidney International·L F FriedB L Kasiske
May 1, 2002·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Tsukasa NakamuraHikaru Koide
Aug 22, 2003·Cardiovascular Drug Reviews·Kouji KajinamiYasushi Saito
Sep 2, 2004·Journal of the American Society of Nephrology : JASN·Anja VerhulstMarc E De Broe
Oct 7, 2004·The American Journal of Pathology·Atsuko KamijoKenjiro Kimura
Feb 8, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Murray Epstein, Vito M Campese
Apr 15, 2005·Clinical and Experimental Nephrology·Toshihiko IshimitsuHiroaki Matsuoka
Apr 28, 2005·International Journal of Clinical Practice·R Y A MukhtarJ P D Reckless
Jun 23, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Toshiki HimedaTsutomu Araki

❮ Previous
Next ❯

Citations

Oct 16, 2008·Clinical and Experimental Hypertension : CHE·Tsukasa NakamuraKoichi Node
Feb 23, 2013·Current Medical Research and Opinion·Dragana NikolicUNKNOWN Lipid and Blood Pressure Meta-Analysis Collaboration Group
Feb 26, 2016·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Xiaole SuHong Zhang
Jun 24, 2011·Kidney International·Robert G FassettWendy E Hoy
Dec 5, 2008·Transplant International : Official Journal of the European Society for Organ Transplantation·Adrian LiewAnantharaman Vathsala
Nov 8, 2011·British Journal of Clinical Pharmacology·Jean Davignon
Jul 25, 2006·Clinica Chimica Acta; International Journal of Clinical Chemistry·Atsuko Kamijo-IkemoriKenjiro Kimura
Sep 11, 2013·International Journal of Cardiology·Dragana NikolicUNKNOWN Lipid and Blood Pressure Meta-Analysis Collaboration Group
Jun 1, 2014·The Cochrane Database of Systematic Reviews·Suetonia C PalmerGiovanni F M Strippoli
Mar 31, 2011·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Pedro Marques da Silva
Jun 20, 2020·The Cochrane Database of Systematic Reviews·Stephen P AdamsJames M Wright
Nov 13, 2013·Expert Review of Cardiovascular Therapy·Vivencio BarriosJosé L Zamorano
Aug 21, 2008·Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum·Maurice M A L Pelsers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Related Papers

Clinica Chimica Acta; International Journal of Clinical Chemistry
Maurice M A L PelsersJ F Glatz
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
Julia M HofstraJack F M Wetzels
© 2021 Meta ULC. All rights reserved